Sunesis Pharmaceuticals, Inc. (SNSS) was a big mover last session, as the company saw its shares rise nearly 8% on the day. The share price increased following the company’s announcement that its CEO Daniel Swisher will present at the Cantor Fitzgerald Inaugural Healthcare Conference on Jul 8. The news led to far more shares changing hands than in a normal session, breaking the recent trend of the company, as the stock is now trading above the volatile price range of $2.39 to $3.01 over the past one-month time frame.
The stock has witnessed two upward estimate revisions in the past 30 days. The Zacks Consensus Estimate also moved up over the same time frame, suggesting that more solid trading could be ahead for Sunesis Pharmaceuticals. So make sure to keep an eye on this stock going forward to see if the latest jump can turn into more strength down the road.
Sunesis Pharmaceuticals sports a Zacks Rank #1 (Strong Buy), while its Earnings ESP is 0.00%.
Investors in the med-biomed/gene industry may also consider Achillion Pharmaceuticals, Inc. (ACHN), carrying the same rank as Sunesis Pharmaceuticals.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment